California’s Penumbra, Inc., will see its aspiration thrombectomy system for ischemic stroke revascularization on the agenda at this week’s International Stroke Conference 2018 meeting (ISC 2018) in Los Angeles.
Penumbra has a growing portfolio of products for use in a range of neuro procedures including the Penumbra System®, a fully integrated system designed specifically for mechanical thrombectomy by aspiration. The company’s neuro embolization systems are designed to meet the unique challenges of aneurysm coiling, vessel sacrifice and other neurovascular malformations. The Penumbra SMART COIL® is a 10-size, detachable, platinum embolization coil system specifically engineered to offer smooth, controlled coil delivery using the latest innovations in coil design and material science. The Penumbra Coil 400™ is a large-volume, detachable, platinum coil system engineered to offer four times the volume of a 10-size coil to efficiently embolize large aneurysms and other large, complex lesions. Finally, there’s the Artemis™ Neuro Evacuation Device, designed specifically for the controlled evacuation of fluids and tissues from the ventricular system and cerebrum.
The ISC will see results of the independent, prospective, randomized controlled COMPASS Trial (A Comparison of Direct Aspiration vs. Stent Retriever as a First Approach) presented by J. Mocco, M.D., M.S., Ichan School of Medicine at Mount Sinai, New York. The multi-center COMPASS Trial compared mechanical thrombectomy with the ADAPT (A Direct Aspiration First Pass Technique) approach to stent retrievers in patients presenting with acute ischemic stroke (AIS) within six hours of symptom onset. The COMPASS Trial planned to enroll approximately 270 patients at up to 20 centers..
In addition, results of the company-sponsored PROMISE Study (Reperfusion with ADAPT Technique using ACE™68 and ACE64 is Safe and Effective in Large Vessel Occlusions of the Anterior Circulation) will be presented by Peter Schramm, M.D., Universitätsklinikum Schleswig-Holstein, Lübeck, Germany. The PROMISE Study was a prospective, single-arm multi-center study that enrolled 204 patients across 20 European centers using ADAPT with the Penumbra System® as frontline treatment.
Attendees will also have the opportunity to learn more about the company’s portfolio of products, including the Penumbra System, Penumbra SMART COIL® System and Artemis™ Neuro Evacuation Device, at the Penumbra booth #521 in the Science and Technology Hall.
Source: Penumbra, Inc.